Streptococcus agalactiae

Clinical analysis of cases of neonatal Streptococcus agalactiae sepsis

S. J. Zeng, Tang, X. S., Zhao, W. L., Qiu, H. X., Wang, H., Feng, Z. C., Zeng, S. J., Tang, X. S., Zhao, W. L., Qiu, H. X., Wang, H., and Feng, Z. C., Clinical analysis of cases of neonatal Streptococcus agalactiae sepsis, vol. 15, p. -, 2016.

With the advent of antibiotic resistance, pathogenic bacteria have become a major threat in cases of neonatal sepsis; however, guidelines for treatment have not yet been standardized. In this study, 15 cases of neonatal Streptococcus agalactiae sepsis from our hospital were retrospectively analyzed. Of these, nine cases showed early-onset and six cases showed late-onset sepsis. Pathogens were characterized by genotyping and antibiotic sensitivity tests on blood cultures.

In silico prediction of conserved vaccine targets in Streptococcus agalactiae strains isolated from fish, cattle, and human samples

U. P. Pereira, Soares, S. C., Blom, J., Leal, C. A. G., Ramos, R. T. J., Guimarães, L. C., Oliveira, L. C., Almeida, S. S., Hassan, S. S., Santos, A. R., Miyoshi, A., Silva, A., Tauch, A., Barh, D., Azevedo, V., and Figueiredo, H. C. P., In silico prediction of conserved vaccine targets in Streptococcus agalactiae strains isolated from fish, cattle, and human samples, vol. 12, pp. 2902-2912, 2013.

Streptococcus agalactiae (Lancefield group B; group B streptococci) is a major pathogen that causes meningoencephalitis in fish, mastitis in cows, and neonatal sepsis and meningitis in humans. The available prophylactic measures for conserving human and animal health are not totally effective and have limitations. Effective vaccines against the different serotypes or genotypes of pathogenic strains from the various hosts would be useful.

Subscribe to Streptococcus agalactiae